MEN1 and multiple endocrine neoplasia type 1: Although no preclinical models or clinical direct evidence have been produced in the MEN1 setting, patients with particularly aggressive pituitary adenomas associated with MEN1 syndrome might be considered for either AIP gene analysis or expression and functional protein assessments, which could help explain the aggressive phenotype.